株探米国株
英語
エドガーで原本を確認する
6-K 1 tm2517246d1_6k.htm FORM 6-K

 

 

 

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 

 

 

Form 6-K

 

 

 

REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE
13a-16 OR 15d-16 UNDER
THE SECURITIES EXCHANGE ACT OF 1934

 

For the month of June 2025

 

Commission File Number 001-40376

 

 

 

Waterdrop Inc.

(Translation of registrant’s name into English)

 

 

 

Block C, Wangjing Science and Technology Park

No. 2 Lize Zhonger Road, Chaoyang District, Beijing

People’s Republic of China

(Address of principal executive office)

 

 

 

Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F. Form 20-F  x Form 40-F  ¨

 

 

 

 


 

EXHIBIT INDEX

 

Exhibit No.   Description
99.1   Press Release— Waterdrop Inc. Announces First Quarter 2025 Unaudited Financial Results

 

 


 

SIGNATURES

 

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

 

  Waterdrop Inc.
   
  By: /s/ Xiaoying Xu
  Name: Xiaoying Xu
  Title: Head of Finance
   
Date: June 5, 2025  

 

 

 

EX-99.1 2 tm2517246d1_ex99-1.htm EXHIBIT 99.1

 

Exhibit 99.1

 

Waterdrop Inc. Announces First Quarter 2025 Unaudited Financial Results

 

BEIJING, June 5, 2025 - Waterdrop Inc. (“Waterdrop”, the “Company” or “we”) (NYSE: WDH), a leading technology platform dedicated to insurance and healthcare service with a positive social impact, today announced its unaudited financial results for the three months ended March 31, 2025.

 

Financial and Operational Highlights for the First Quarter of 2025

 

Profit growth with stable liquidity: In the first quarter of 2025, net profit attributable to our ordinary shareholders reached RMB108.2 million (US$14.9 million), marking a solid increase of 34.2% year-over-year. We continued to generate positive operating cash flow during the first quarter of 2025.

 

Accelerated business growth: The first-year premiums (“FYP”) generated through our insurance business reached RMB2,092.4 million (US$288.3 million) during the first quarter of 2025, representing an increase of 19.3% year over year. Net operating revenue was RMB753.7 million (US$103.9 million), representing an increase of 7.0% year over year.

 

Expanded crowdfunding coverage: As of March 31, 2025, around 475 million people cumulatively had donated an aggregate of RMB68.8 billion to 3.47 million patients through Waterdrop Medical Crowdfunding.

 

Steadfast performance in patient recruitment: As of March 31, 2025, the Company had cumulatively enrolled 11,217 patients into 1,281 clinical trial programs through the E-Find Platform.

 

Mr. Peng Shen, Founder, Chairman, and Chief Executive Officer of Waterdrop, commented, “We achieved remarkable growth in the first quarter of 2025, kicking off the year with robust operational and financial outcomes. Both revenue and profits grew on a year-on-year and quarter-on-quarter basis.

 

In line with our annual growth objectives, our insurance business maintained a strong upward trajectory. We refined our public domain user acquisition strategies and improved services for private domain users, leading to a notable 30.1% year-over-year increase in short-term insurance premium. Product innovation remains a top priority, as highlighted by the upgrade of ‘Jiehaoyun’, our industry-first product, to version 5.0. Furthermore, we recently introduced a revolutionary Million Medical Insurance product that uniquely offers both a health declaration waiver and guaranteed renewal for five consecutive years. Despite headwinds from product iteration, our long-term insurance premiums grew by 27.6% quarter-on-quarter, demonstrating operational resilience.

 

Waterdrop Medical Crowdfunding further enhanced its risk control framework through ongoing upgrades, improving the rigor of campaign validation processes. This quarter, we expanded our verification platform to cover 92% of domestic cities. The system now enables smoother user-led verification of critical credibility factors like housing, vehicle ownership, and income data. These improvements deliver more reliable and efficient risk management.

 

Our digital clinical trial solution revenue sustained its growth momentum this quarter, reflecting an 11.5% increase compared to the same period last year. We collaborated with a total of 185 pharmaceutical companies and contract research organizations (“CROs”). Meanwhile, we enrolled 822 patients and initiated services for 77 new programs during the first quarter of 2025.

 

We are pleased to report that Waterdrop Guardian AI applications are playing increasingly critical roles in both internal and external use cases. For instance, the penetration of our ‘AI Insurance Expert - Medical Insurance’ has further expanded and facilitated over 2 million yuan in monthly premiums this quarter. Additionally, our ‘AI Service Quality Copilot’ has boosted unit operational efficiency by 83% since its launch. Beyond internal initiatives, we have partnered with four Property and Casualty insurers to pilot AI-driven applications in the auto insurance sector, collaborating to set industry benchmarks.

 

Every strategic action we take is anchored in our objective of maximizing shareholder value. The Company distributed approximately US$7.3 million in cash dividends this quarter and repurchased a cumulative total of approximately 54.2 million ADSs from the open market as of May 31, 2025.

 

Our long-standing commitment to user-centric philosophy and AI investment laid the foundation for our achievements. Looking ahead to the upcoming quarters of 2025, we will leverage our proven business know-how to accelerate operational growth, creating greater value to both users and shareholders.”

 

 


 

Financial Results for the First Quarter of 2025

 

Operating revenue, net

 

Net operating revenue for the first quarter of 2025 increased by 7.0% year-over-year to RMB753.7 million (US$103.9 million) from RMB704.7 million for the same period of 2024. On a quarter-over-quarter basis, net operating revenue increased by 9.7%.

 

· Insurance-related income includes insurance brokerage income and technical service income. Insurance brokerage income represents brokerage commissions earned from insurance companies. Technical service income is derived from providing technical services including customer relationship maintenance, customer complaint management, claim review, and user referral services, among other things, to insurance companies, insurance brokers, and agency companies. Our insurance-related income amounted to RMB658.0 million (US$90.7 million) in the first quarter of 2025, representing an increase of 8.4% year-over-year from RMB606.8 million for the first quarter of 2024, which was mainly due to an increase in insurance brokerage income. On a quarter-over-quarter basis, insurance-related income increased by 13.0%.

 

· Crowdfunding service fees represent the service income earned when patients successfully withdraw the proceeds from their crowdfunding campaigns. Our role is to operate the Waterdrop Medical Crowdfunding platform to provide crowdfunding related services through the internet, enabling patients with significant medical bills to seek help from caring hearts through technology (the “medical crowdfunding services”). Our medical crowdfunding services generally consist of providing technical and internet support, managing, reviewing and supervising the crowdfunding campaigns, providing comprehensive risk management and anti-fraud measures, and facilitating the collection and transfer of the funds. For the first quarter of 2025, we generated RMB67.1 million (US$9.3 million) in service fees, remaining stable compared with the service fees of RMB67.4 million for the first quarter of 2024. On a quarter-over-quarter basis, crowdfunding service fees increased by 3.1%.

 

· Digital clinical trial solution income represents the service income earned from our customers mainly including biopharmaceutical companies and leading biotechnology companies. We match qualified and suitable patients for enrollment in clinical trials for our customers and generate digital clinical trial solution revenue for successful matches and we typically charge our customers a fixed unit price per successful match. For the first quarter of 2025, our digital clinical trial solution income amounted to RMB23.0 million (US$3.2 million), representing an increase of 11.5% from RMB20.6 million in the same period of 2024. On a quarter-over-quarter basis, digital clinical trial solution income decreased by 9.9%.

 

Operating costs and expenses

 

Operating costs and expenses increased by 3.0% year over year to RMB677.8 million (US$93.4 million) for the first quarter of 2025. On a quarter-over-quarter basis, operating costs and expenses increased by 6.9%.

 

· Operating costs increased by 13.0% year over year to RMB374.2 million (US$51.6 million) for the first quarter of 2025, as compared with RMB331.2 million for the first quarter of 2024, which was primarily driven by (i) an increase of RMB37.7 million in costs of referral and service fees, (ii) an increase of RMB2.8 million in the costs for the digital clinical trial solution consultants team, and (iii) an increase of RMB1.7 million in personnel costs. On a quarter-over-quarter basis, operating costs increased by 15.6% from RMB323.8 million, primarily due to (i) an increase of RMB28.3 million in costs of referral and service fees, and (ii) an increase of RMB8.4 million in the costs for the crowdfunding consultants team.

 

· Sales and marketing expenses decreased by 5.4% year over year to RMB172.4 million (US$23.8 million) for the first quarter of 2025, as compared with RMB182.1 million for the same quarter of 2024. The decrease was primarily due to (i) a decrease of RMB5.9 million in outsourced sales and marketing service fees to third parties, (ii) a decrease of RMB5.6 million in personnel costs and share-based compensation expenses, partially offset by (iii) an increase of RMB4.5 million in marketing expenses for third-party traffic channels. On a quarter-over-quarter basis, sales and marketing expenses decreased by 5.3% from RMB182.0 million, primarily due to (i) a decrease of RMB7.5 million in marketing expenses for third-party traffic channels, and (ii) a decrease of RMB1.9 million in outsourced sales and marketing service fees to third parties.

 

· General and administrative expenses decreased by 15.8% year over year to RMB74.9 million (US$10.3 million) for the first quarter of 2025, compared with RMB89.0 million for the same quarter of 2024. The year-over-year variance was due to (i) a decrease of RMB9.8 million in professional service fees, and (ii) a decrease of RMB4.0 million in allowance for credit losses. On a quarter-over-quarter basis, general and administrative expenses increased by 1.7% from RMB73.7 million, due to (i) an increase of RMB4.7 million in allowance for credit losses, partially offset by (ii) a decrease of RMB2.6 million in professional service fees.

 

 


 

· Research and development expenses remained stable at RMB56.2 million (US$7.8 million) for the first quarter of 2025, maintaining nearly the same level as RMB56.0 million for the same period of 2024. On a quarter-over-quarter basis, research and development expenses increased by 3.6% from RMB54.3 million. The increase was primarily due to an increase of RMB1.7 million in personnel costs and share-based compensation expenses.

 

Operating profit for the first quarter of 2025 was RMB75.9 million (US$10.5 million), as compared with RMB46.4 million for the first quarter of 2024 and RMB53.0 million for the fourth quarter of 2024.

 

Interest income for the first quarter of 2025 was RMB33.8 million (US$4.7 million), as compared with RMB39.8 million for the first quarter of 2024 and RMB35.8 million for the fourth quarter of 2024.

 

Income tax expense for the first quarter of 2025 was RMB13.3 million (US$1.8 million), as compared with RMB8.6 million for the first quarter of 2024 and RMB1.9 million for the fourth quarter of 2024.

 

Net profit attributable to the Company’s ordinary shareholders for the first quarter of 2025 was RMB108.2 million (US$14.9 million), as compared with RMB80.6 million for the same period of 2024, and RMB99.6 million for the fourth quarter of 2024.

 

Adjusted net profit attributable to the Company’s ordinary shareholders (non-GAAP1) for the first quarter of 2025 was RMB130.0 million (US$17.9 million), as compared with RMB98.4 million for the same period of 2024, and RMB107.1 million for the fourth quarter of 2024.

 

Cash position2

 

As of March 31, 2025, cash position of the Company was RMB3,543.3 million (US$488.3 million), as compared with RMB3,670.3 million as of December 31, 2024.

 

Share Repurchase Programs

 

Pursuant to the share repurchase programs launched in September 2021, September 2022, September 2023 and September 2024, respectively, we had cumulatively repurchased approximately 54.2 million ADSs from the open market with cash for a total consideration of approximately US$106.6 million as of May 31, 2025.

 

Supplemental Information

 

We organize and report our business in the following operating segments:

 

· Insurance, which mainly includes insurance brokerage service and technical service;

· Crowdfunding, which mainly includes crowdfunding service; and

· Others, which do not individually or in the aggregate meet the quantitative and qualitative thresholds to be individually reportable and are aggregated.

 

The table below sets forth the segment operating results, with the three-month comparative figures retrospectively adjusted to conform to this presentation.

 

1 See the sections entitled “Non-GAAP Financial Measure” and “Reconciliations of GAAP and Non-GAAP Results” for more information about the non-GAAP measures referred to in this announcement.
2 Cash position includes cash and cash equivalents, short-term investments, and long-term debt investments included in long-term investments.

 

 


 

    For the Three Months Ended  
    March 31, 2024     December 31, 2024     March 31, 2025  
    RMB     RMB     RMB     USD  
Operating revenue, net                                
Insurance     606,777       582,442       657,988       90,673  
Crowdfunding     67,350       65,138       67,131       9,251  
Others     30,573       39,244       28,575       3,938  
Total consolidated operating revenue, net     704,700       686,824       753,694       103,862  
Operating costs and expenses                                
Insurance     (477,614 )     (479,856 )     (506,575 )     (69,808 )
Crowdfunding     (99,587 )     (87,147 )     (97,299 )     (13,408 )
Others     (62,005 )     (45,177 )     (54,000 )     (7,442 )
Operating profit/(loss)                                
Insurance     129,163       102,586       151,413       20,865  
Crowdfunding     (32,237 )     (22,009 )     (30,168 )     (4,157 )
Others     (31,432 )     (5,933 )     (25,425 )     (3,504 )
Total segment operating profit     65,494       74,644       95,820       13,204  
Unallocated items*     (19,130 )     (21,684 )     (19,927 )     (2,746 )
Total consolidated operating profit     46,364       52,960       75,893       10,458  
Total other income     42,781       40,443       41,690       5,745  
Consolidated profit before income tax     89,145       93,403       117,583       16,203  

 

* The share-based compensation represents unallocated items in the segment information because our management does not consider this as part of the segment operating performance measure.

 

Exchange Rate

 

This announcement contains translations of certain RMB amounts into U.S. dollars (“USD” or “US$”) at specified rates solely for the convenience of the reader. Unless otherwise stated, all translations from RMB to USD were made at the rate of RMB7.2567 to US$1.00, the noon buying rate in effect on March 31, 2025 in the H.10 statistical release of the Federal Reserve Board. The Company makes no representation that the RMB or USD amounts referred could be converted into USD or RMB, as the case may be, at any particular rate or at all. For analytical presentation, all percentages are calculated using the numbers presented in the financial statements contained in this earnings release.

 

Non-GAAP Financial Measure

 

The Company uses non-GAAP financial measure, adjusted net profit attributable to our ordinary shareholders, in evaluating the Company’s operating results and for financial and operational decision-making purposes. Adjusted net profit attributable to our ordinary shareholders represents net profit attributable to our ordinary shareholders excluding share-based compensation expense attributable to our ordinary shareholders, foreign currency exchange gain or losses, and impact of terminating the mutual aid plan on non-GAAP adjustments. Such adjustments have no impact on income tax.

 

The non-GAAP financial measure is not presented in accordance with U.S. GAAP and may be different from non-GAAP methods of accounting and reporting used by other companies. The non-GAAP financial measure has limitations as analytical tools and when assessing the Company’s operating performance, investors should not consider it in isolation, or as a substitute for net loss or other consolidated statements of comprehensive loss data prepared in accordance with U.S. GAAP. The Company encourages investors and others to review its financial information in its entirety and not rely on a single financial measure. Investors are encouraged to review the Company’s historical non-GAAP financial measure to the most directly comparable GAAP measure. Adjusted net profit attributable to our ordinary shareholders presented here may not be comparable to similarly titled measure presented by other companies. Other companies may calculate similarly titled measure differently, limiting its usefulness as a comparative measure to our data.

 

The Company mitigates these limitations by reconciling the non-GAAP financial measure to the most comparable U.S. GAAP performance measure, all of which should be considered when evaluating the Company’s performance.

 

For more information on the non-GAAP financial measure, please see the table captioned “Reconciliation of GAAP and Non-GAAP Results” set forth at the end of this press release.

 

 


Safe Harbor Statement

 

This press release contains statements that may constitute “forward-looking” statements pursuant to the “safe harbor” provisions of the U.S. Private Securities Litigation Reform Act of 1995. These forward-looking statements can be identified by terminology such as “will,” “expects,” “anticipates,” “aims,” “future,” “intends,” “plans,” “believes,” “estimates,” “likely to” and similar statements. Among other things, quotations in this announcement, contain forward-looking statements. Waterdrop may also make written or oral forward-looking statements in its periodic reports to the SEC, in its annual report to shareholders, in press releases and other written materials and in oral statements made by its officers, directors or employees to third parties. Statements that are not historical facts, including statements about Waterdrop’s beliefs, plans and expectations, are forward-looking statements. Forward-looking statements involve inherent risks and uncertainties. A number of factors could cause actual results to differ materially from those contained in any forward-looking statement, including but not limited to the following: Waterdrop’s mission, goals and strategies; Waterdrop’s future business development, financial condition and results of operations; the expected growth of the insurance, medical crowdfunding and healthcare industry in China; Waterdrop’s expectations regarding demand for and market acceptance of our products and services; Waterdrop’s expectations regarding its relationships with consumers, insurance carriers and other partners; competition in the industry and relevant government policies and regulations relating to insurance, medical crowdfunding and healthcare industry. Further information regarding these and other risks is included in Waterdrop’s filings with the SEC. All information provided in this press release is as of the date of this press release, and Waterdrop does not undertake any obligation to update any forward-looking statement, except as required under applicable law.

 

Conference Call Information

 

Waterdrop’s management team will hold a conference call on June 5, 2025 at 8:00 AM U.S. Eastern Time (8:00 PM Beijing/Hong Kong Time on the same day) to discuss the financial results. Dial-in details for the earnings conference call are as follows:

 

International: 1-412-317-6061
United States Toll Free: 1-888-317-6003
Hong Kong Toll Free: 800-963976
Hong Kong: 852-58081995
Mainland China: 4001-206115
Chinese Line (Mandarin) Entry Number: 0072517
English Interpretation Line (Listen-only Mode) Entry Number: 8162178

 

Participants can choose between the Chinese and the English interpretation lines. Please note that the English interpretation option will be in listen-only mode. Please dial in 15 minutes before the call is scheduled to begin and provide the Elite Entry Number to join the call.

 

Telephone replays will be accessible two hours after the conclusion of the conference call until June 12, 2025 by dialing the following numbers:

 

United States Toll Free: 1-877-344-7529
International: 1-412-317-0088
Chinese Line Access Code: 9960990
English Interpretation Line Access Code: 6469856

 

A live and archived webcast of the conference call will also be available at the Company’s investor relations website at http://ir.waterdrop-inc.com/.

 

About Waterdrop Inc.

 

Waterdrop Inc. (NYSE: WDH) is a leading technology platform dedicated to insurance and healthcare service with a positive social impact. Founded in 2016, with the comprehensive coverage of Waterdrop Insurance Marketplace and Waterdrop Medical Crowdfunding, Waterdrop aims to bring insurance and healthcare service to billions through technology. For more information, please visit www.waterdrop-inc.com.

 

For investor inquiries, please contact

Waterdrop Inc.

IR@shuidi-inc.com

 

 


 

WATERDROP INC.

UNAUDITED CONDENSED CONSOLIDATED BALANCE SHEETS

(All amounts in thousands, unless otherwise noted)

 

    As of  
    December 31, 2024     March 31, 2025  
    RMB     RMB     USD  
Assets                        
Current assets                        
Cash and cash equivalents     986,323       1,158,059       159,585  
Restricted cash     520,588       603,924       83,223  
Short-term investments     1,612,619       778,068       107,221  
Accounts receivable, net     716,206       768,855       105,951  
Current contract assets     619,436       632,525       87,164  
Amount due from related parties     257       270       37  
Prepaid expense and other assets     182,641       192,849       26,575  
Total current assets     4,638,070       4,134,550       569,756  
Non-current assets                        
Non-current contract assets     153,749       171,226       23,596  
Property, equipment and software, net     240,024       240,846       33,189  
Intangible assets, net     153,011       152,979       21,081  
Long-term investments     1,114,160       1,649,792       227,347  
Right of use assets, net     46,872       36,970       5,095  
Deferred tax assets     27,028       21,278       2,932  
Goodwill     80,751       80,751       11,128  
Total non-current assets     1,815,595       2,353,842       324,368  
Total assets     6,453,665       6,488,392       894,124  
                         
Liabilities, Mezzanine Equity and Shareholders’ Equity                        
Current liabilities                        
Amount due to related parties     10,616       10,851       1,495  
Insurance premium payables     537,344       624,202       86,017  
Accrued expenses and other current liabilities     704,035       791,425       109,061  
Short-term loans     198,373       -       -  
Current lease liabilities     34,573       30,973       4,268  
Total current liabilities     1,484,941       1,457,451       200,841  
Non-current liabilities                        
Non-current lease liabilities     10,971       5,707       786  
Deferred tax liabilities     84,185       91,680       12,634  
Total non-current liabilities     95,156       97,387       13,420  
Total liabilities     1,580,097       1,554,838       214,261  
                         
Mezzanine Equity                        
Redeemable non-controlling interests     76,133       72,193       9,948  
                         
Shareholders’ equity                        
Class A ordinary shares     112       113       16  
Class B ordinary shares     27       27       4  
Treasury stock     (15 )     (16 )     (2 )
Additional paid-in capital     6,832,214       6,784,389       934,914  
Accumulated other comprehensive income     159,550       163,106       22,477  
Accumulated deficit     (2,194,453 )     (2,086,258 )     (287,494 )
Total shareholders’ equity     4,797,435       4,861,361       669,915  
Total liabilities, mezzanine equity and shareholders’ equity     6,453,665       6,488,392       894,124  

 

 


 

WATERDROP INC.

UNAUDITED CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE INCOME 

(All amounts in thousands, except for share and per share data, or otherwise noted)

 

    For the Three Months Ended  
    March 31, 2024     December 31, 2024     March 31, 2025  
    RMB     RMB     RMB     USD  
Operating revenue, net     704,700       686,824       753,694       103,862  
Operating costs and expenses(i)                                
Operating costs     (331,243 )     (323,836 )     (374,218 )     (51,569 )
Sales and marketing expenses     (182,146 )     (182,038 )     (172,396 )     (23,757 )
General and administrative expenses     (88,961 )     (73,725 )     (74,943 )     (10,327 )
Research and development expenses     (55,986 )     (54,265 )     (56,244 )     (7,751 )
Total operating costs and expenses     (658,336 )     (633,864 )     (677,801 )     (93,404 )
Operating profit     46,364       52,960       75,893       10,458  
Other income                                
Interest income     39,804       35,802       33,814       4,660  
Foreign currency exchange gain/(loss)     1,514       (963 )     (2,103 )     (290 )
Others, net     1,463       5,604       9,979       1,375  
Profit before income tax     89,145       93,403       117,583       16,203  
Income tax expense     (8,588 )     (1,936 )     (13,328 )     (1,837 )
Net profit     80,557       91,467       104,255       14,366  
Net loss attributable to mezzanine equity classified as non-controlling interests shareholders     (75 )     (8,148 )     (3,940 )     (543 )
Net profit attributable to ordinary shareholders     80,632       99,615       108,195       14,909  
Other comprehensive income:                                
Foreign currency translation adjustment, net of tax     25,143       89,187       (14,056 )     (1,937 )
Unrealized (loss)/gain on available for sale investments, net of tax     -       (29,330 )     17,612       2,427  
Total comprehensive income     105,700       151,324       107,811       14,856  
Total comprehensive loss attributable to mezzanine equity classified as non-controlling interests shareholders     (75 )     (8,148 )     (3,940 )     (543 )
Total comprehensive income attributable to ordinary shareholders     105,775       159,472       111,751       15,399  
Weighted average number of ordinary shares used in computing net profit per share                                
Basic     3,696,619,172       3,620,987,566       3,620,380,862       3,620,380,862  
Diluted     3,756,462,107       3,699,552,300       3,711,999,000       3,711,999,000  
Net profit per share attributable to ordinary shareholders                                
Basic     0.02       0.03       0.03       0.00  
Diluted     0.02       0.03       0.03       0.00  

 

(i) Share-based compensation expenses are included in the operating costs and expenses as follows.

 

    For the Three Months Ended  
    March 31, 2024     December 31, 2024     March 31, 2025  
    RMB     RMB     RMB     USD  
Sales and marketing expenses     (1,820 )     (1,692 )     (1,899 )     (262 )
General and administrative expenses     (14,327 )     (17,336 )     (15,527 )     (2,140 )
Research and development expenses     (2,983 )     (2,656 )     (2,501 )     (344 )
Total     (19,130 )     (21,684 )     (19,927 )     (2,746 )

 

 


 

WATERDROP INC.

RECONCILIATIONS OF GAAP AND NON-GAAP RESULTS

(All amounts in thousands, unless otherwise noted)

 

    For the Three Months Ended  
    March 31, 2024     December 31, 2024     March 31, 2025  
    RMB     RMB     RMB     USD  
Net profit attributable to the Company’s ordinary shareholders     80,632       99,615       108,195       14,909  
Add:                                
Share-based compensation expense attributable to the Company’s ordinary shareholders     19,260       21,502       19,750       2,722  
Foreign currency exchange (gain)/ loss     (1,514 )     963       2,103       290  
Impact of terminating the mutual aid plan (ii)     -       (14,985 )     -       -  
Adjusted net profit attributable to the Company’s ordinary shareholders     98,378       107,095       130,048       17,921  

 

(ii) This represents the reversal of the difference between estimated cost of medical expense coverage and actual payment.